Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 2/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9529830 | 0.89 | PTGES (0.50) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL7677328 | 0.88 | ALDH1A1 (0.52) | AGTR2AGTR1KDM4EALDH1A1LMNA | |
| SCHEMBL9422984 | 0.88 | KDM4E (0.53) | AGTR2AGTR1KDM4EALDH1A1LMNA | |
| SCHEMBL9422890 | 0.87 | KDM4E (0.53) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL9422780 | 0.87 | KDM4E (0.52) | AGTR2AGTR1KDM4EALDH1A1LMNA | |
| SCHEMBL7056945 | 0.86 | KDM4E (0.52) | AGTR2AGTR1KDM4EALDH1A1LMNA | |
| SCHEMBL9422757 | 0.86 | KDM4E (0.52) | AGTR2AGTR1KDM4EALDH1A1LMNA | |
| SCHEMBL9422775 | 0.85 | KDM4E (0.53) | AGTR2AGTR1KDM4EALDH1A1LMNA | |
| SCHEMBL9422793 | 0.85 | ALDH1A1 (0.55) | AGTR2AGTR1ALDH1A1 | |
| SCHEMBL9422974 | 0.84 | KDM4E (0.56) | AGTR2AGTR1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | claimed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | claimed |
| US-5294631-A | Substituted benzimidazoles useful as angiotension II receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-15 | — | — | US | claimed |
| EP-0525129-A4 | SUBSTITUTED BENZIMIDAZOLES | — | 1993-03-24 | — | — | EP | claimed |
| EP-0525129-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-03 | — | — | EP | claimed |
| WO-1991016313-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-31 | — | — | WO | claimed |
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5656650-A | TREATING HYPERTENSION | SMITHKLINE BEECHAM CORP. | 1997-08-12 | — | — | US | disclosed |
| US-5294631-A | Substituted benzimidazoles useful as angiotension II receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0565634-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-20 | — | — | EP | disclosed |
| WO-1993006828-A1 | MEDICAMENT FOR THE TREATMENT OF ANXIETY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
| EP-0525129-A4 | SUBSTITUTED BENZIMIDAZOLES | — | 1993-03-24 | — | — | EP | disclosed |
| EP-0525129-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1992010097-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1991016313-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | AGTR2 3926/4885AGTR1 4001/4885KDM4E 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.